TB-500 for Cardioprotection: Off-Label Evidence Summary

What Is TB-500 and Is It Approved for Any Use?

TB-500 is a synthetic peptide corresponding to amino acids 17 to 23 of thymosin beta-4 (Tβ4), a 43-amino-acid protein found in virtually all nucleated mammalian cells. The fragment retains the actin-binding domain believed responsible for much of Tβ4's biological activity. TB-500 carries no FDA-approved indication for any condition in humans. The FDA has not granted it Investigational New Drug (IND) status as a commercially distributed product, and it appears on several compounding pharmacy prohibition lists.

How TB-500 Differs From Full-Length Thymosin Beta-4

Full-length Tβ4 has been studied under IND applications by RegeneRx Biopharmaceuticals in wound healing and dry-eye trials, but those programs have not progressed to approval. TB-500 is a distinct, truncated fragment sold primarily as a research chemical. Buyers should not assume that animal-model findings from full-length Tβ4 studies map directly onto TB-500, because receptor binding kinetics and tissue distribution differ between the two molecules.

Legal and Regulatory Status

The FDA prohibits the compounding of peptides that are essentially copies of commercially available drugs or that lack adequate clinical evidence of safety. As of 2025, the agency's list of bulk substances not eligible for compounding under Section 503A includes several peptides, and TB-500 is not on the approved bulk substances list either [1]. Athletes should note that the World Anti-Doping Agency (WADA) has prohibited thymosin beta-4 and its fragments since 2012 under the S2 Peptide Hormones category [2].

Mechanism of Action: Why Cardioprotection Is Biologically Plausible

The interest in TB-500 for cardioprotection comes from Tβ4's role in embryonic heart development and post-injury cardiac repair. Three converging pathways explain the preclinical signal.

Actin Sequestration and Cytoskeletal Stabilization

Tβ4 binds G-actin in a 1:1 ratio, buffering the free actin pool and preventing pathological cytoskeletal collapse during ischemia-reperfusion injury. In cardiomyocytes exposed to simulated ischemia, Tβ4 reduced actin stress fiber dissolution by approximately 40% compared with vehicle controls in one in-vitro model published in Circulation Research [3]. Cytoskeletal integrity is required for mitochondrial anchoring; its loss accelerates apoptosis during the first hours after coronary occlusion.

Akt and PI3K Survival Signaling

Tβ4 activates integrin-linked kinase (ILK), which in turn phosphorylates Akt at Ser473. In a murine left-anterior-descending (LAD) ligation model, systemic Tβ4 administration increased myocardial pAkt levels by roughly 3-fold at 24 hours post-infarction, correlating with a 26% reduction in TUNEL-positive cardiomyocytes [4]. The ILK-Akt axis also promotes VEGF secretion, which may explain the angiogenic effect seen in longer-duration animal experiments.

Epicardial Progenitor Activation

One of the more striking findings in the Tβ4 literature is epicardial reactivation. Smart et al. (2011) in Nature demonstrated that systemic Tβ4 priming in mice before LAD ligation reactivated quiescent epicardial cells, which then differentiated into functional cardiomyocytes and smooth muscle cells, reducing infarct area and improving fractional shortening by 10 percentage points versus controls [5]. This study used full-length Tβ4, not the TB-500 fragment specifically, which is an important distinction for interpreting applicability.

Preclinical Evidence: Animal Model Data

Animal data represent the bulk of the cardioprotection evidence base for Tβ4 and TB-500. The quality is reasonable within its tier, but the translational gap to humans is large.

Rodent Myocardial Infarction Models

Multiple rodent studies using LAD ligation report consistent infarct-size reductions with Tβ4 administration. A 2004 paper in Annals of the New York Academy of Sciences (Bock-Marquette et al.) showed that intraperitoneal Tβ4 given after LAD ligation reduced infarct area by 36% and improved ejection fraction by 9 percentage points at four weeks in C57BL/6 mice [6]. A subsequent 2009 study in the same species found that delayed administration (starting 24 hours post-MI) still reduced fibrosis by 25% at eight weeks, suggesting a therapeutic window beyond the acute phase.

The TB-500 fragment specifically, rather than full-length Tβ4, has been tested in fewer published models. One 2016 rodent study reported a 28% reduction in infarct size with the AcSDKP fragment at 2 mg/kg intraperitoneal dosing, but that study has not been independently replicated in peer-reviewed literature as of this writing [7].

Porcine Ischemia-Reperfusion Models

Porcine hearts are anatomically closer to human hearts than rodent hearts, making porcine data more predictive. A 2014 study funded by RegeneRx used full-length Tβ4 in a porcine ischemia-reperfusion model and observed a statistically significant 20% reduction in infarct size by cardiac MRI at four weeks (P<0.05), along with preserved wall motion in the peri-infarct zone [8]. No published porcine study has used the isolated TB-500 fragment as the active agent.

Summary of Animal Evidence

| Model | Agent | Infarct Reduction | EF Improvement | Source | |---|---|---|---|---| | Mouse LAD ligation | Full Tβ4 | 36% | +9 pp | Bock-Marquette 2004 [6] | | Mouse LAD ligation (delayed) | Full Tβ4 | 25% fibrosis reduction | NR | Thymosin review 2009 | | Rodent (fragment-specific) | TB-500 fragment | 28% | NR | [7] | | Porcine IR model | Full Tβ4 | 20% | Preserved | RegeneRx 2014 [8] |

NR = not reported; IR = ischemia-reperfusion; pp = percentage points.

Human Evidence: What Exists and What Does Not

This section is short for a reason. Human evidence for TB-500 in cardioprotection is effectively absent.

Completed Human Trials

No completed randomized controlled trial has tested TB-500 or full-length Tβ4 specifically for a cardiac endpoint in humans. RegeneRx conducted Phase I and Phase II trials of full-length Tβ4 for dry-eye disease and sternal wound healing, establishing a preliminary safety profile at doses up to 42 mg systemic exposure, but cardiac endpoints were not primary or secondary outcomes in those trials [9].

Registered but Incomplete Trials

A search of ClinicalTrials.gov as of July 2025 returns no active or completed trials registering TB-500 for any cardiac indication. One suspended Phase II trial (NCT01311518) tested full-length Tβ4 in acute MI patients but was terminated early due to enrollment difficulties and did not reach statistical power for any endpoint [10]. That trial's interim data showed no safety signals at the doses tested, but efficacy conclusions cannot be drawn.

What the Absence of Human Data Means Clinically

The GRADE Working Group framework rates evidence from well-conducted animal studies with no human RCT confirmation as Very Low quality. A GRADE Very Low rating means the true effect is probably substantially different from the estimated effect, and clinical decisions cannot be reliably based on it [11]. Physicians reviewing TB-500 requests from patients should communicate this clearly: the biology is interesting, the animal data are consistent, but the human data do not yet exist.

The HealthRX clinical team uses the following decision framework when evaluating off-label peptide requests for cardioprotection. A prescription or recommendation for TB-500 is appropriate only when all four gates are satisfied: (1) an IND or equivalent regulatory authorization is in place, (2) the patient is enrolled in a formal study with IRB oversight, (3) standard-of-care pharmacotherapy (beta-blocker, ACE inhibitor or ARB, statin, antiplatelet) has been optimized, and (4) informed consent explicitly addresses the Very Low GRADE evidence level and the absence of long-term human safety data. If any gate fails, the answer is no.

GRADE Evidence Rating Explained

GRADE assigns one of four certainty levels: High, Moderate, Low, or Very Low. For TB-500 in cardioprotection, the rating is Very Low for three reasons.

Study Design Limitation

All published efficacy data come from animal models (GRADE starting point: Low) with no upgrading factors.

Indirectness

Most animal work used full-length Tβ4, not the TB-500 fragment. The fragment shares the actin-binding LKKTET motif but lacks the full C-terminus, altering receptor interaction profiles. This indirectness downgrades the evidence by one additional level.

Publication Bias Concern

The TB-500 research chemical market is commercially active, creating incentives to publish positive findings. No large negative animal study has been published, which raises the possibility of a file-drawer problem. The Cochrane Bias Methods Group considers this a sufficient reason to apply a further downgrade in the absence of a prospective trial registry [12].

The resulting GRADE certainty: Very Low. Quoting directly from the GRADE handbook: "Very low certainty: We have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect." [11]

Safety Profile: Known and Unknown

Adverse Effects Reported in Animal Studies

At doses used in rodent cardioprotection models (1 to 4 mg/kg), no organ toxicity was reported in necropsy findings across the major published studies. Tβ4 at high doses in some cancer-biology experiments showed pro-angiogenic activity that raised theoretical concern about tumor growth promotion, given that VEGF upregulation is part of its mechanism. No tumor promotion was observed in the MI-model animals over the typical 4-to-8-week follow-up windows, but those windows are too short to evaluate oncogenic risk [13].

Human Safety Data

In the RegeneRx Phase I/II dry-eye and wound-healing trials, the most common adverse events were local injection-site reactions (reported in 18% of subjects receiving subcutaneous Tβ4) and mild fatigue (12%). No serious cardiac adverse events, thrombotic events, or deaths were attributed to the drug across those programs [9]. These data cover full-length Tβ4 at doses and routes not directly comparable to the subcutaneous self-administration pattern typical of TB-500 research chemical use.

Unknown Risks From Unregulated Sourcing

TB-500 purchased outside a clinical trial comes from research chemical suppliers whose products are not subject to FDA manufacturing standards. A 2021 analysis of peptide research chemicals purchased from online vendors found that 23% of samples contained the labeled peptide at less than 85% purity, and 11% contained detectable endotoxin levels above the FDA's 5 EU/kg threshold for injectable products [14]. Endotoxin contamination in injectable peptides can cause fever, sepsis, and death. This sourcing risk is independent of TB-500's pharmacological profile and applies to any unregulated injectable peptide.

Current Standard of Care for Cardioprotection

Patients asking about TB-500 for cardioprotection are often doing so in the context of preventing or recovering from myocardial infarction. The established pharmacological options for this indication are well-evidenced.

Guideline-Recommended Agents

The 2022 AHA/ACC Guideline for the Management of Heart Failure and the 2023 ACC/AHA Guideline for Coronary Artery Disease recommend the following for post-MI cardioprotection, all with Class I, Level A evidence [15]:

• High-intensity statin therapy (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg daily)
• ACE inhibitor or ARB in patients with reduced ejection fraction (EF <40%)
• Beta-blocker therapy (metoprolol succinate, carvedilol, or bisoprolol) titrated to goal heart rate
• Dual antiplatelet therapy with aspirin 81 mg plus a P2Y12 inhibitor for 12 months post-ACS
• SGLT2 inhibitor (dapagliflozin or empagliflozin) for patients with HFrEF, based on DAPA-HF (N=4,744) and EMPEROR-Reduced (N=3,730) trial data [16, 17]

Where TB-500 Would Need to Fit

If TB-500 eventually proves safe and effective in humans, it would most likely be evaluated as an adjunct to, not a replacement for, the agents above. The Smart et al. (2011) Nature paper described Tβ4 as promoting myocardial regeneration through a mechanism distinct from hemodynamic unloading or neurohumoral blockade. That mechanistic separation suggests additive rather than overlapping benefit, but this remains speculative until human trial data exist [5].

Dosing and Administration Used in Research Settings

No clinically validated dose exists for TB-500 in humans for any cardiac indication. The following represents what has been used in animal research and, separately, what circulates in self-administration communities. This information is provided for educational context only and does not constitute a prescription or clinical recommendation.

Animal Research Doses

Rodent studies used intraperitoneal doses of 1 to 6 mg/kg. Scaling to a 70 kg human by body surface area conversion (using the FDA's standard 37-fold conversion factor from mouse) gives an approximate human-equivalent dose of 27 to 163 mg total, which is substantially higher than the subcutaneous doses discussed in the self-administration literature. This dosing gap makes direct extrapolation unreliable [18].

Self-Administration Patterns Reported Online

Anecdotal reports from biohacking forums describe subcutaneous doses of 2 to 2.5 mg administered two to three times per week, typically for 4-to-6-week cycles. No pharmacokinetic data validate subcutaneous bioavailability for TB-500 in humans. The peptide's plasma half-life has not been established in any human PK study.

Physician Communication Points

When a patient asks about TB-500 for cardioprotection, three specific statements should appear in the clinical conversation.

First, TB-500 is not FDA-approved for any use, and obtaining it outside a clinical trial places the patient outside any regulatory safety net.

Second, the evidence base is GRADE Very Low, meaning the probability that the human effect matches the animal effect is low. The history of cardiac pharmacology contains several agents (phosphodiesterase inhibitors, antiarrhythmics from CAST) that showed promising preclinical profiles and caused harm or no benefit in human trials [19].

Third, the compounding and sourcing risk is real and independent of efficacy. Endotoxin contamination in injectable research peptides has caused hospitalizations. Any patient self-injecting unregulated peptides should be counseled about signs of injection-site infection and systemic inflammatory response.